Get the Stockscreener App
0.4655
6.04%
0.0265
After Hours:
.45
-0.0155
-3.33%
Aditxt Inc stock is traded at $0.4655, with a volume of 222.52K.
It is up +6.04% in the last 24 hours and down -53.31% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.439
Open:
$0.44
24h Volume:
222.52K
Relative Volume:
0.09
Market Cap:
$1.68M
Revenue:
$749.50K
Net Income/Loss:
$-29.60M
P/E Ratio:
-0.00124
EPS:
-376.0263
Net Cash Flow:
$-22.09M
1W Performance:
-27.50%
1M Performance:
-53.31%
6M Performance:
-86.62%
1Y Performance:
-98.59%
1-Day Range:
$0.4164
$0.4757
1-Week Range:
$0.4164
$0.65
52-Week Range:
$0.4164
$35.90
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Aditxt Inc Stock (ADTX) Latest News
Aditxt Inc: Rising -98.90% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
ADTX stock touches 52-week low at $0.54 amid market challenges - Investing.com
Aditxt subsidiary seeks $2M for prostate cancer test - Investing.com
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients - StockTitan
Is Aditxt Inc (ADTX) worth investing in despite its overvalued state? - US Post News
Prepare Yourself for Liftoff: Aditxt Inc (ADTX) - SETE News
Ratio Examination: Aditxt Inc (ADTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024 - Quantisnow
Aditxt extends senior note maturity to September 30 By Investing.com - Investing.com Australia
Aditxt extends senior note maturity to September 30 By Investing.com - Investing.com Canada
Aditxt extends senior note maturity to September 30 - Investing.com
Aditxt extends senior note maturity to September 30 By Investing.com - Investing.com UK
Aditxt Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - The InvestChronicle
Stock Market Recap: Aditxt Inc (ADTX) Concludes at 0.79, a -11.70 Surge/Decline - The Dwinnex
Pearsanta appoints Christopher Mitton as President By Investing.com - Investing.com Australia
Pearsanta appoints Christopher Mitton as President - Investing.com
Pearsanta appoints Christopher Mitton as President By Investing.com - Investing.com Canada
Pearsanta appoints Christopher Mitton as President - Investing.com India
ADTXAditxt, Inc. Latest Stock News & Market Updates - StockTitan
Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) - Quantisnow
Pearsanta appoints Christopher Mitton as President By Investing.com - Investing.com UK
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) - Elk Valley Times
Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™) - StockTitan
ADTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia
500: Something went wrong - Investing.com India
ADTX stock touches 52-week low at $0.88 amid market challenges - Investing.com
ADTX stock touches 52-week low at $0.88 amid market challenges - Investing.com UK
Aditxt extends Appili acquisition deadline to November 19 - Investing.com
Evofem Biosciences amends merger agreement with Aditxt By Investing.com - Investing.com Australia
Aditxt extends Appili acquisition deadline to November 19 By Investing.com - Investing.com Australia
Aditxt extends Appili acquisition deadline to November 19 By Investing.com - Investing.com UK
ADTX’s Stock Dilemma: Aditxt Inc’s Market Performance and Outlook - The InvestChronicle
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics - Elk Valley Times
Aditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics - Quantisnow
Appili Therapeutics Modifies Acquisition Deal with Aditxt - TipRanks
Market Update: Aditxt Inc (ADTX) Sees Negative Movement, Closing at 0.95 - The Dwinnex
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt - Yahoo Finance
Evofem Biosciences amends merger agreement with Aditxt - Investing.com
Evofem Biosciences amends merger agreement with Aditxt By Investing.com - Investing.com UK
ADTX Stock Earnings: Aditxt Reported Results for Q2 2024 - MSN
ADTX Stock Earnings: Aditxt Reported Results for Q2 2024 - InvestorPlace
Aditxt (NASDAQ:ADTX) Stock Quotes, Forecast and News Summary - Benzinga
Short Interest in Aditxt, Inc. (NASDAQ:ADTX) Increases By 81.5% - Defense World
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 - StreetInsider.com
Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 - StockTitan
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025 - BioSpace
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025 - StockTitan
Aditxt shareholders approve strategic proposals - Investing.com
Aditxt shareholders approve strategic proposals - Investing.com India
Aditxt shareholders approve strategic proposals By Investing.com - Investing.com Australia
Aditxt Announces the Successful Passage of all Proposals at Recent Annual Shareholders' Meeting, Setting the Stage for 2024 and 2025 Strategic Plans - Quantisnow
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):